Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals

LONDON,April 30,2022 -- Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals,contrary to a PR Newswire announcement issued today indicating that Opiant Pharmaceuticals and Hikma have entered into a commercialisation and license agreement for OPNT003,Nasal Nalmefene,in Europe and the UK.

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI: 549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/stable Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years,we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK,we are a global company with a local presence across the United States (US),the Middle East and North Africa (MENA) and Europe,and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers,and the people they care for,and by thinking creatively and acting practically,we provide them with a broad range of branded and non-branded generic medicines. Together,our 8,700 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner,and through our venture capital arm,are helping bring innovative health technologies to people around the world. For more information,please visit:www.hikma.com

©2022 Hikma Pharmaceuticals PLC. All rights reserved.